No abstract available.
Diabetes Insipidus*

PURPOSE:Growth retardation is a serious clinical problem in children with chronic renal failure(CRF). Dialysis and renal transplantation do not provide an improvement in growth velocity. Possible causes of growth retardation are nutritional deficiency, electrolyte imbalance, uremia, renal asteodystrophy and chronic anemia. However, catch-up growth cannot be achieved after correcting these factors. There is no concordance about disturbances of growth hormone(GH)-insulin-like growth factor-I (IGF-I) axis. in CRF. This study was designed to evaluate the growth status, IGF-I, GH and the effect of GH in CRF. METHODS:Twelve children with CRF(five were treated conservative, seven were transplanted) were included. IGF-I, stimulated GH, 24 hour integrated concentration of GH (IC-GH)were measured. Six were given rhGH(0.1U/kg/day) for average one year. RESULTS: 1)Growth velocity(GV) was 3.2+/-0.8cm/yr(conservative therapy:3.3+/-0.7, transplanted:2.9+/-0.8). Height standard deveation score(SDS) was -2.4+/-1.3cm/yr(conservative therapy group:-3.3+/-1.4, transplanted group:-1.3+/-0.4). Bone age lagged 2.1+/-13yr behind chronological age. 2) IGF-I concentrations were normal. 3)Stimulated GH levels were normal(16.6+/-3.3ng/ml) except one patient. Twenty- four hour IC-GH were less than 3.2ng/ml in 4 patients. 4)After GH therapy, GV increased 3.3+/-0.7cm/yr to 5.4+/-0.8cm/yr and Ht SDS increased -3.3+/-1.4 to -2.9+/-1.5 in the conservatively treated group. GV increased 2.9+/-0.8cm/yr to 5.5+/-1.8cm/yr and Ht SDS increased -1.3+/-0.4 to -0.8+/-0.5 in the transplanted group. CONCLUSION: Stimulated GH was normal but spontaneous secretion of GH was decreased in some patients with CRF. This neurosecretory dysfunction may be one causative factor in CRF. For these patients GH replacement therapy will be effective in promoting growth.
Anemia ; Axis, Cervical Vertebra ; Child* ; Dialysis ; Growth Hormone* ; Humans ; Insulin-Like Growth Factor I ; Kidney Failure, Chronic* ; Kidney Transplantation ; Malnutrition ; Uremia

No abstract available.
Child* ; Humans ; Insulin-Like Growth Factor I* ; Plasma* ; Somatomedins*

No abstract available.
Hyperparathyroidism, Primary

Congenital hypothyroidism is one of the most common endocrine disease in childhood and it causes not only mental retardation but also growth retardation. There were many papers about evaluation of developmental outcome in congenital hypothyroidism. The aim of this study was to evaluate growth outcome in congenital hypothyroidism. We evaluated 65 patients with congenital hypothyroidism diagnosed at Yonsei University College of Medicine. The results were summerized as follows; 1) The Male to female ratio was 1:1.4 2) Among the 65 patients, under 1 year of age with 16 cases (24.6%), 1~4 years with 19 cases (29.2%), 5~10 years with 22 cases (33.8%), above 10 years with 8 cases (12.3%). 3) Among the 65 patients, 30 cases (46%) had ectopic thyroid, 18 cases (28%) had dyshormonogeneses, 10 cases (15%) had hypoplasia and 7 cases (11%) had aplasia. 4) At the initial diagnosis, all the patients showed decreased T3, T4 and increased TSH level. 5) Before treatment, bone age and height age were delayed but they were normalized after treatment. 6) There was correlation between age of initial treatment and current height percentile. 7) There was significant correlation between initial T3 level and height age delay. 8) In the 4 cases who were diagnosed and treated before the age of 4, final adult height would be achieved within normal range. In conclusion, delayed growth due to congenital hypothyroidism would be prevented by early diagnosis and treatment. Therefore, the recognition of the importance of early diagnosis and treatment is emphasized.
Adult ; Congenital Hypothyroidism* ; Diagnosis ; Early Diagnosis ; Endocrine System Diseases ; Female ; Humans ; Intellectual Disability ; Male ; Reference Values ; Thyroid Dysgenesis

No abstract available.
Child* ; Diabetes Mellitus* ; Humans ; Insulin* ; Sex Hormone-Binding Globulin*

No abstract available.
Child* ; Growth Hormone* ; Humans

No abstract available.
Antibody Formation* ; Humans*

No abstract available.

PURPOSE: Short stature is the most constant finding in Turner syndrome. Short stature in Turner syndrome has lately received considerable attention, mostly because of recent attemp to improve growth by hormonal treatments; growth hormone, oxandrolone, estrogen. The aim of this study was to find out whether growth promoting treatment would improve final height in girls with Turner syndrome. METHODS:Seventy-one girls with the clinical chracteristics Turner syndrome verified by karyotype analysis were entered into this study. The following selection criteria for final adult height were used; Chronological age of more than 14years old, bone age of more than 15years old and growth velocity of less than 0.5cm per 6months. Analysis was performed by means of multiple regression analysis between descriptive data; modality of treatment with oxandrolone and/or estrigen, parental height, karyotype and final adult height. RESULTS: 1) The final adult height of untreated Turner syndrome was 138.9+/-3.9cm. 2)The final adult height in 29 GH treated Turner girls was 143.9+/-6.5cm, significant higher value than 42 GH untreated Turner girls height, 139.8+/-5.2cm(p<0.01). 3) The final height in GH only group and combined group were 141.2+/-6.0cm, 146.2+/-6.2cm, respectively. The combined therapy was more effective than GH therapy(p<0.01). 4) The final height in 32 patients with karyotype of 45,X was 141.6+/-5.6cm, and that of 31 structural aberration group was 140.3+/-6.2cm. There was no significant difference between two groups. But in mosaicism, only numeric abnormalities, the final height 145.9+/-6.1cm was much more higher than other two groups(p<0.05). 5) The final adult height in Turner syndrome was in good correlation with target height. Final adult height(cm)= 1.01*Target height(cm)- 4.97 r=0.51, p<0.05. 6) There was positive correlation between final adult height and height SDS at start GH treatment and negative correlation with age at start GH treatment. The delta height (final height - height at start treatment) correlate with GH treatment duration. CONCLUSIONS:The final adult height in Turner syndrome in a given ethinic or national population varies in the same way as adult height in normal women. Growth hormone therapy may increase final height in Turner syndrome irrespective of ethinic or national difference. Further growth was observed in GH combined with estrogen or oxandrolone.
Adult* ; Estrogens ; Female ; Growth Hormone ; Humans ; Karyotype ; Mosaicism ; Oxandrolone ; Parents ; Patient Selection ; Turner Syndrome*